Astaxanthin as a potential therapeutic agent in polycystic ovary syndrome: a review of its antioxidant, anti-inflammatory, and metabolic mechanisms - Quiz - MDSpire

Astaxanthin as a potential therapeutic agent in polycystic ovary syndrome: a review of its antioxidant, anti-inflammatory, and metabolic mechanisms

  • By

  • Jialai Wang

  • Ying Yang

  • Ziwei Wang

  • Chengdong Liu

  • Yanhua Han

  • Xiaoke Wu

  • Hui Chang

  • July 13, 2026

Share

Original Source(s)

Astaxanthin as a potential therapeutic agent in polycystic ovary syndrome: a review of its antioxidant, anti-inflammatory, and metabolic mechanisms

  • by Jialai Wang, Ying Yang, Ziwei Wang, Chengdong Liu, Yanhua Han, Xiaoke Wu, Hui Chang

  • July 13, 2026

Related Content

Non-linear saturation threshold of gonadotropin dose on cumulative live birth rates in advanced-age women with polycystic ovary syndrome: a retrospective cohort study

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.